AstraZeneca's blood cancer drug Calquence's tablet form gets approval in EU
artJazz


The European Commission (EC) approved AstraZeneca's (NASDAQ:AZN) tablet formulation of Calquence (acalabrutinib) to treat adult patients with chronic lymphocytic leukemia (CLL).
The EC approval was backed by positive opinion from a panel of the European Medicines Agency (EMA) and was backed by data from the trials called ELEVATE-PLUS.

The British pharma giant said that the studies showed that Calquence capsule and tablet formulations are bioequivalent.
Tablet form can be co-administered with gastric acid-reducing agents allowing more patients to have the drug, according to the company.
Calquence is approved as a capsule formulation for CLL in the U.S. and EU. The drug's tablet form was approved in the U.S. in August 2022.